Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update
Conference Call and Webcast Today at 4:30 p.m. ET What to Expect for the Remainder of 2023 XACIATO™: receipt of...
Conference Call and Webcast Today at 4:30 p.m. ET What to Expect for the Remainder of 2023 XACIATO™: receipt of...
Company Introduces Multimedia Resources to Bring Awareness of SADLAVAL, QC / ACCESSWIRE / November 8, 2023 / As daylight saving...
Two late-breaking high-impact oral presentations of the Phase 3 PROTECT Study of FILSPARI®(sparsentan) in IgAN and Phase 3 DUPLEX Study...
Studies address cost-effectiveness and budget impact of INPEFA, an inhibitor of SGLT2 and SGLT1 INPEFA recently approved by FDA for treatment...
BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
Mr. Garner brings over 25 years of pharmaceutical industry experienceTHE WOODLANDS, Texas, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals,...
Booth #2450-22 (DiMe Virtual First Care Pavilion) and Booth #4950-5 (CareQuest Systemic Health Pavilion)METUCHEN, N.J.--(BUSINESS WIRE)--Dentistry.One, a virtual-first dental care...
Direct Access Lab Company is Among Leaders in the Health and Medical SectorATLANTA, GA / ACCESSWIRE / September 28, 2023...
INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure SCORED was one of two randomized, double-blind, placebo-controlled Phase...
WEST CHESTER, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology...
The first academic center activated to enroll, led by an instrumental investigator who participated in Femasys’ earlier FemBloc studies -FemBloc...
INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure LX9211 is an investigational, non-opioid treatment for diabetic peripheral...
--Reached agreement with FDA on single Phase 3 clinical trial design to expand treatment population to include all hospitalized adult...
SIKLOS® (hydroxyurea) is now covered by State Medicaid programs in 19 states Medunik USA (member of Duchesnay Pharmaceutical Group) is...
FILSPARI® (sparsentan) achieved a clinically meaningful difference vs. irbesartan in eGFR total slope (1.0 mL/min/1.73m2 per year) and eGFR chronic...
MIAMI, FL, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
ATLANTA, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs...
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
Grant from Bill & Melinda Gates Foundation will facilitate development of AI-assisted applications and tools to enable healthcare professionals with...
Additional Providers Increase Biospecimen Access for Researchers Focused on Cervical, Uterine and Breast Cancers, as well as Reproductive Health, Cardiovascular...